Ticker Details
Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
IPO Date:	August 23, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$85.67M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.60%
Avg Daily Range (30 D):	$0.04 | 2.77%
Avg Daily Range (90 D):	$0.06 | 3.19%

Institutional Daily Volume
Avg Daily Volume:	.76M
Avg Daily Volume (30 D):	1.66M
Avg Daily Volume (90 D):	1.5M

Trade Size
Avg Trade Size (Sh.):	70
Avg Trade Size (Sh.) (30 D):	331
Avg Trade Size (Sh.) (90 D):	282

Institutional Trades
Total Institutional Trades:	3,231
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$1.67M
Avg Institutional Trade (90 D):	$.96M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.58M
Avg Closing Trade (30 D):	$1.67M
Avg Closing Trade (90 D):	$1.67M
Avg Closing Volume:	49.21K

News

Apr 7, 2026 @ 7:46 PM Pomerantz Law Firm Announces the Filing of a Class... Source: Pomerantz Llp

Apr 7, 2026 @ 4:00 PM DEADLINE ALERT for PSFE, INO, KD: Law Offices of H... Source: Law Offices Of Howard G. Smith

Apr 6, 2026 @ 9:38 PM Bragar Eagel & Squire, P.C. Urgently Reminds Inves... Source: Bragar Eagel & Squire, P.C.

Apr 6, 2026 @ 8:00 PM Shareholders that lost money on Atara Biotherapeut... Source: Levi & Korsinsky, Llp

Apr 6, 2026 @ 1:32 AM UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDIN... Source: Rosen Law Firm

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.81	$.31	$-1.81
Diluted EPS	$-1.81	$.31	$-1.81
Revenue	$.07M	$M	$.07M
Gross Profit
Net Income / Loss	$-84.95M	$3.76M	$-84.95M
Operating Income / Loss	$-86.82M	$-17.48M	$-86.82M
Cost of Revenue
Net Cash Flow	$-21.54M	$7.71M	$-21.54M
PE Ratio

Splits
Jan 25, 2024	1:12
Jun 09, 2014	1:4
Jun 06, 2014	1:4
Sep 13, 2004	1:4